To evaluate the relationship of C1orf63 expression with clinicopathological features, tumor sections from 182 primary breast cancer patients were immunostained to detect the expression of C1orf63, and these patients were subsequently divided into two groups according to their IHC scores: 44 (24.2 %) tumors expressing C1orf63 [C1orf63 (+) group] and 138 (75.8 %) tumors lacking C1orf63 expression [C1orf63 (−) group]. Here, RSRP1 is linked to neoplasm.